Literature DB >> 15526142

Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers.

W H Jost1, A Kohl, S Brinkmann, G Comes.   

Abstract

PURPOSE: This randomized controlled trial was performed to compare the novel botulinum toxin type A free of complexing proteins (NT 201) with the marketed preparation BOTOX degrees regarding efficacy and tolerability.
METHODS: Fourteen healthy volunteers received a single intramuscular injection into the extensor digitorum brevis (EDB) muscle of either 4 units NT 201, or 4 units of BOTOX degrees randomised by foot. Compound muscle action potential (CMAP) measurements were recorded for up to 90 days after injection.
RESULTS: Both drugs produced a maximum decline between Day 7 and Day 14. At Day 90, administration of both drugs resulted in approximately a 40% CMAP decline as compared to baseline. Duration of paralytic effect was comparable in both groups, at all response thresholds tested. Both drugs were well tolerated.
CONCLUSION: The effects of small amounts of NT 201 and BOTOX degrees injected into the EDB muscle are comparable in terms of efficacy, time to onset of action, duration of action, and tolerability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526142     DOI: 10.1007/s00702-004-0234-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  18 in total

1.  Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.

Authors:  P Roggenkämper; W H Jost; K Bihari; G Comes; S Grafe
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

2.  A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.

Authors:  Matthias Imhof; Ulrich Kühne
Journal:  J Clin Aesthet Dermatol       Date:  2011-10

Review 3.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

4.  Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke.

Authors:  Andrea Santamato; Francesco Panza; Maurizio Ranieri; Vincenza Frisardi; Maria Francesca Micello; Serena Filoni; Francesca Fortunato; Domenico Intiso; Mario Basciani; Giancarlo Logroscino; Pietro Fiore
Journal:  J Neural Transm (Vienna)       Date:  2012-09-07       Impact factor: 3.575

Review 5.  Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.

Authors:  Wolfgang H Jost; Jörg Blümel; Susanne Grafe
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity.

Authors:  Andrea Santamato; Francesco Panza
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 7.  Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction.

Authors:  Koenraad De Boulle; Steven Fagien; Boris Sommer; Richard Glogau
Journal:  Clin Interv Aging       Date:  2010-04-26       Impact factor: 4.458

Review 8.  Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment.

Authors:  Alessio Baricich; Alessandro Picelli; Andrea Santamato; Stefano Carda; Alessandro de Sire; Nicola Smania; Carlo Cisari; Marco Invernizzi
Journal:  Clin Drug Investig       Date:  2018-11       Impact factor: 2.859

9.  Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study.

Authors:  Welf Prager; Eva K Bee; Isabel Havermann; Ina Zschocke
Journal:  Clin Interv Aging       Date:  2013-04-24       Impact factor: 4.458

10.  Functional influence of botulinum neurotoxin type A treatment (Xeomin®) of multifocal upper and lower limb spasticity on chronic hemiparetic gait.

Authors:  Maurizio Falso; Rosalba Galluso; Andrea Malvicini
Journal:  Neurol Int       Date:  2012-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.